Premature ovarian insufficiency in patients with systemic lupus erythematosus on cyclophosphamide: a systematic review and meta-analysis - Scorecard - MDSpire

Premature ovarian insufficiency in patients with systemic lupus erythematosus on cyclophosphamide: a systematic review and meta-analysis

  • By

  • Manuel Ramón García-Sáenz

  • Claudia Ramírez-Rentería

  • Etual Espinosa-Cárdenas

  • Ernesto Sosa-Eroza

  • José Luis Eduardo Doval-Caballero

  • Paulo César Gete Palacios

  • Fabiola Pazos-Pérez

  • Mario César Ocampo-Torres

  • Rocío Catana-Hernández

  • Miguel Ángel Vázquez-Zaragoza

  • Adolfo Camargo-Coronel

  • Juan Rodrigo Gómez-Bernal

  • Aldo Ferreira-Hermosillo

  • May 28, 2026

  • 0 min

Share

Clinical Scorecard: Premature Ovarian Insufficiency Among Women with Systemic Lupus Erythematosus Treated with Cyclophosphamide: A Systematic Review and Meta-Analysis

At a Glance

CategoryDetail
Condition
Key MechanismsCyclophosphamide (CYC) therapy in systemic lupus erythematosus (SLE) as reported in the study.
Target Population
Care Setting

Key Highlights

  • Pooled prevalence of POI in SLE treated with CYC is 15% (95% CI 7-26%)
  • Substantial heterogeneity in prevalence estimates across studies (I2 = 85%)
  • Reduced prevalence of POI in studies published after 2005 (9%) compared to pre-2005 (29%)
  • Age at exposure is a significant predictor of POI prevalence

Guideline-Based Recommendations

Diagnosis

  • Standardized diagnostic criteria for POI are needed as per the study findings.
  • Consider both clinical surrogates and endocrinologic criteria for diagnosis.

Management

  • Gonadotropin-releasing hormone analogues (GnRHa) may be used as ovarian-protective co-therapy during CYC treatment as indicated in the study.

Monitoring & Follow-up

  • Monitor for signs of estrogen deficiency and associated health risks as discussed in the study.

Risks

  • Increased risks of cardiovascular disease, osteoporosis, and impaired quality of life due to estrogen deficiency as noted in the study.

Patient & Prescribing Data

Women of reproductive age diagnosed with SLE

CYC is indicated for severe, organ-threatening manifestations of SLE

Clinical Best Practices

  • Implement fertility counseling for women undergoing CYC treatment as suggested in the study.
  • Adopt lower-dose CYC regimens where appropriate as indicated in the study.

Related Resources & Content

Original Source(s)

Related Content